Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Mallinckrodt
Boehringer Ingelheim
Medtronic
Dow

Last Updated: November 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,553,498

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,553,498 protect, and when does it expire?

Patent 7,553,498 protects PROTONIX and is included in one NDA.

Protection for PROTONIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-four patent family members in twenty-seven countries.

Summary for Patent: 7,553,498
Title:Pantoprazole multiparticulate formulations
Abstract:A method of treating gastroesophageal reflux disease (GERD), ulcers of the stomach or duodenum, or Zollinger-Ellison Syndrome in a human, by administering pantoprazole sodium multiparticulates is described. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water, an enteric coat on the subcoat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose (hypromellose) and water.
Inventor(s): Venkata Ramana Rao; Sripriya (Mahwah, NJ), Shah; Syed M. (East Hanover, NJ), Tatapudy; Hanumantharao (Suffern, NY), Saunders; Richard William (Palisades, NY), Fawzi; Mahdi (Morristown, NJ), Nagi; Arwinder (Thiells, NY), Singh; Shailesh (Bardonia, NY), Hasan; Sumon A (Monroe, NY)
Assignee: Wyeth (Madison, NJ)
Application Number:11/731,626
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 7,553,498

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Wyeth Pharms PROTONIX pantoprazole sodium FOR SUSPENSION, DELAYED RELEASE;ORAL 022020-001 Nov 14, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,553,498

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 045956   Start Trial
Australia 2004278037   Start Trial
Brazil PI0415014   Start Trial
Canada 2539982   Start Trial
China 1886119   Start Trial
Colombia 5690538   Start Trial
Costa Rica 8318   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
McKesson
Moodys
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.